Eliglustat for Gaucher Disease: Quantifying the Impact of Pharmacogenetic Status on DDIs Case Study Eliglustat for Gaucher Disease: Quantifying the Impact of Pharmacogenetic Status on DDIs In 2014, Eliglustat (Cerdelga®) was approved by the FDA as the first long-term treatment for…Certara2021年8月26日
Aripiprazole lauroxil: PBPK for Dosing Regimen and DDI Identification Case Study Aripiprazole lauroxil: PBPK for Dosing Regimen and DDI Identification Aripiprazole lauroxil (Aristada®) was approved by the FDA for treating schizophrenia in adults in October…Certara2021年8月12日
PBPK Assists with DDI Prediction Without a Rifampin Study for Cobimetinib Case Study PBPK Assists with DDI Prediction Without a Rifampin Study for Cobimetinib Cobimetinib (Cotellic®), approved by the US FDA in 2015, is a kinase inhibitor for treating…Certara2021年8月12日
Succeeding in Value Communication: Introduction Blog バリューコミュニケーションの成功:新薬の紹介 Drawn from the experiences of the BaseCase Consulting Team, this is the introduction to ‘Succeeding…Certara2021年8月5日
DDI Regulatory Poster Child using the Simcyp Simulator: Ibrutinib (Imbruvica®) Case Study Simcyp Simulatorを使用するDDIレギュレトリーの広告塔:Ibrutinib (Imbruvica®) Pharmacylics and J&J sought to bring ibrutinib, its new tyrosine kinase inhibitor therapy targeting rare…Certara2021年7月29日
What is BaseCase? ビデオ What is BaseCase? Developing interactive and easy-to-use stakeholder engagement content market access, medical affairs, and sales field teams…Certara2021年7月20日
Voxelotor for Treating Sickle Cell Disease: Leveraging Dose Prediction Model for DDI Prediction Without Any Clinical Studies Case Study 鎌状赤血球症治療用のVoxelotor:用量予測モデルを活用して臨床試験を実施することなくDDIを予測 In November 2019, the US FDA granted accelerated approval for Oxbryta™ (voxelotor) tablets for the…Certara2021年7月14日
Preparing for High Stakes Meetings; How to Best Convey a New Drug’s Value to Payers Blog Preparing for High Stakes Meetings; How to Best Convey a New Drug’s Value to Payers This blog post includes key takeaways from the opening session of Certara’s first Strategic Evidence…Certara2021年6月18日
Three Pathways have emerged in Innovative Access Agreements On-Demand Webinar Three Pathways have emerged in Innovative Access Agreements The days of simply determining the market demand for a new drug as a function…Certara2021年6月11日
Outcomes Based Agreements On-Demand Webinar Outcomes Based Agreements The days of simply determining the market demand for a new drug as a function…Certara2021年6月11日